Head and neck sarcomas: treatment outcomes in a tertiary referral center in Argentina

Yanzon, Alejandro; Gómez, Natalia Lucía; Picco, Pedro; Boccalatte, Luis Alejandro; Cayol, Federico; Larrañaga, Juan; Figari, Marcelo

doi:10.1007/s10006-021-00944-0

Cited by 6 publications

(7 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 5‐year survival rate in previous literatures ranged from 10% to 30%, and was 8% in another study (13 RISHN patients, single institution) 28,29 . Significantly worse survival times have been reported for patients with RIS than in those with sporadic (de novo) undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma 30–32 . High‐grade tumors, older age (>60 years), gross positive resection margins, and tumor size >5 cm were predictors of poor sarcoma‐specific survival 33,34 .…”

Section: Discussionmentioning

confidence: 87%

“…28,29 Significantly worse survival times have been reported for patients with RIS than in those with sporadic (de novo) undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. [30][31][32] High-gradetumors, older age (>60 years), gross positive resection margins, and tumor size >5 cm were predictors of poor sarcoma-specific survival. 33,34 Compared to de novo sarcoma, higher grade and more advanced stage are observed in patients with RIS.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Radiation‐induced sarcoma of head and neck: Clinical characteristics and molecular signatures

et al. 2022

View full text Add to dashboard Cite

Background Radiation‐induced sarcoma of the head and neck (RISHN) is a rare yet devastating potential complication of radiotherapy treatment. We aimed to evaluate the clinicopathological characteristics and molecular signatures of RISHN in patients who underwent radiotherapy for head and neck cancer (HNC) to identify high‐risk patients and enable earlier cancer detection. Methods This study retrospectively evaluated 24 sarcoma patients who received radiotherapy for HNC between 1994 and 2019. Patients were divided into two groups based on RISHN latency period. Patient demographics, initial tumor staging, risk factors, and survival between groups were analyzed, and whole‐exome sequencing (WES) of selected samples was performed. Results The median age at diagnosis of RISHN was 54 years, and the male‐to‐female ratio was 2:1. The latency period ranged from 0.8 to 64.4 years (median 6.5 years), with a median survival of 21.5 months. Primary cancer in the oral cavity, treatment with alkylating agents, alcohol consumption, betel nut chewing, and smoking were identified as risk factors for short (<5 years) latency periods. The majority of RISHN cases occurred in the oral cavity (58.3%). WES analysis showed that tumor necrosis factor and cell cycle checkpoint pathways were differentially involved in both patient groups. Conclusions Although case numbers were small, our cohort represents the largest case series of RISHN from a single institution to date. Clinicians must be aware of factors affecting RISHN development and latency, and risk factor identification may lead to earlier detection and prevention in the future.

show abstract

Section: Discussionmentioning

confidence: 87%

Section: Discussionmentioning

confidence: 99%

Radiation‐induced sarcoma of head and neck: Clinical characteristics and molecular signatures

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Sarcomas in the head and neck region are commonly diagnosed in middle-aged adults (Moreira et al, 2020;Yanzon et al, 2021). et al, 2020).…”

Section: Discussionmentioning

confidence: 99%

“…An important finding of this systematic review concerns the age at diagnosis. Sarcomas in the head and neck region are commonly diagnosed in middle‐aged adults (Moreira et al, 2020; Yanzon et al, 2021). Alishahi et al (2015), for example, observed in their retrospective study that individuals with sarcomas had a mean age of 41 years.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Ewing's sarcoma of the head and neck: A systematic review

et al. 2023

View full text Add to dashboard Cite

ObjectiveThe aim of the present study was to conduct a systematic review of head and neck Ewing sarcoma (ES) concerning patients' demographic and clinical features, histopathological findings, treatment, follow‐up, and survival rate.Materials and MethodsAn electronic search was undertaken in four databases. Articles describing case reports or case series were included. Outcomes were evaluated by the Kaplan–Meier method along with Cox regression.ResultsThe search yielded 186 studies describing 227 ES cases. The mean age was 22.7 years, and males were slightly more affected. Interestingly, more than half the cases were diagnosed up to 20 years. The respiratory tract was the most reported site, followed by the jawbones. Clinically, symptomatic swelling or nodules were described, with a mean duration of 4 months. Management involved multimodal treatment regimens. Local recurrence, lymph node and distant metastasis were observed in 10.7%, 12.6%, and 20.3% of cases, respectively. Statistical analysis revealed that older patients with distant metastasis had a lower overall survival rate (p < 0.05).ConclusionThis study provides an overall view of head and neck ES that can assist oral and maxillofacial pathologists with the diagnosis and extend the knowledge of surgeons and oncologists about this condition.

show abstract

Ewing Sarcoma of the Sinonasal Tract: A Scoping Review

Shaari,

Ho,

Patel

et al. 2024

The Laryngoscope

View full text Add to dashboard Cite

ObjectiveEwing sarcoma (ES) is a rare aggressive malignancy that can present in the sinonasal region. The objective of this study is to investigate the demographics, presentation, management, and outcomes of patients with sinonasal ES.Data SourcesPubMed, Web of Science, SCOPUS, CINAHL, and Cochrane Library.Review MethodsA scoping review of cases of sinonasal ES was performed. Inclusion criteria consisted of case reports, series, or retrospective reviews.Results785 total articles were retrieved. 72 articles met inclusion criteria and were included in the final review for a total of 93 cases. 48 (53%) patients were male. Mean age at diagnosis was 26.4 years old (range 1–89). Nasal obstruction (N = 55, 59%), epistaxis (N = 35, 38%), and impaired vision (N = 29, 29%) were the most common symptoms. On examination, 38 (41%) patients had a nasal cavity mass. Most tumors (N = 33, 35%) were located in the maxillary sinus. 44 (47%) were left sided and 4 (4%) were bilateral. The most utilized treatment modalities were surgical resection with adjuvant chemoradiotherapy (N = 27, 29%), chemoradiotherapy alone (N = 24, 26%), and surgical resection with adjuvant chemotherapy (N = 14, 15%). 56 patients had no evidence of disease (60%), 14 patients died with disease (15%), and 9 patients were alive with disease (10%) at the time of follow‐up.ConclusionsTo our knowledge, we report the first scoping review of sinonasal ES. Patients generally present with non‐specific sinonasal symptoms. Surgery with adjuvant chemoradiation is the most common treatment modality for these patients.Level of EvidenceNA Laryngoscope, 2024

show abstract

Head and neck sarcomas: treatment outcomes in a tertiary referral center in Argentina

Cited by 6 publications

References 32 publications

Radiation‐induced sarcoma of head and neck: Clinical characteristics and molecular signatures

Radiation‐induced sarcoma of head and neck: Clinical characteristics and molecular signatures

Ewing's sarcoma of the head and neck: A systematic review

Ewing Sarcoma of the Sinonasal Tract: A Scoping Review

Contact Info

Product

Resources

About